Pfizer Inc. (PFE) exhibits 74.3% gross margins and 5.1% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 19.7x enterprise multiple and 4.8% implied options volatility.
Sustained 74.3% gross profitability converts into 15.1% operating margin and 5.1% ROIC, outpacing sector cost of capital.
ROIC: 5.1% // GM: 74.3%YoY revenue trajectory of -1.6% paired with 5.32% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -1.6% // FCF YLD: 5.32%Altman Z-Score of 2.10 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.10 // F-SCORE: 7/9Trading at 22.0x trailing P/E (20.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 22.0x // EV/EBITDA: 19.7xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $30.52 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 12.4% net margins.
NET MARGIN: 12.4% // D/E: 0.71x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for PFE & activate live FRED threshold breach alerts.